VectivBio Reports Full Year 2021 Financial Results and
Significant Progress Across Multiple Programs with Key Upcoming Catalysts Beginning H2 2022 STARS Phase 3 Program of Apraglutide in Short Bowel...
Luca Santarelli Program Of Apraglutide Vectivbio Holding Ag Nasdaq Significant Progress Across Multiple Programs Short Bowel Syndrome Intestinal Failure
Source: globenewswire.com